Autopsy report · NCT03520985

Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma

“Feasibility (low patient accrual and financial reasons)”

The sponsor’s own words in the registry.

Life of this trial

• Registered 5 months before it started.
• Ran for about 2 years 4 months before it stopped.
• 34 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Swiss Cancer Institute

Sponsor type

University, hospital or other

Conditions

Refractory Multiple Myeloma

Interventions

Pomalidomide; Dexamethasone

Participants

34

Sites

16

Countries

Switzerland

Trials that died the same way

• Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome
  “Due to poor patient recruitment and insufficient financing.” (74% match in meaning)
• Study of Lenalidomide With Vorinostat in Pediatric Patients With High Grade or Progressive CNS Tumors
  “Lack of feasibility to accrue patients in allotted time.” (71% match in meaning)
• SOX as Salvage Treatment in Nasopharyngeal Carcinoma
  “poor accrual of eligible patients” (70% match in meaning)
• Abiraterone-Rechallenge Study for CRPC Patients
  “Lack of Patient accrual” (70% match in meaning)
• TRAUMA HELP: Healing and Analgesia With Propranolol
  “Lack of eligible patient recruits/feasibility considerations.” (69% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.